Gut Bacteria Create a Protein Modification That Damages Liver Mitochondria
A novel gut microbiome metabolite chemically modifies liver proteins, impairing mitochondrial function and insulin signaling in obesity and fatty liver disease.
Summary
Scientists discovered that gut bacteria produce phenylacetic acid (PAA), which creates a previously unknown chemical tag on liver proteins called lysine phenylacetylation (Kpaa). This modification accumulates in obese mice and humans with fatty liver disease, where it disrupts mitochondrial function and impairs how cells respond to insulin. A key protective enzyme called SIRT3 can remove these harmful tags. When PAA modified a specific heat-shock protein (HSP60), it triggered a cellular stress response in mitochondria. In people with obesity and metabolic liver disease, SIRT3 levels were low while Kpaa levels were high, suggesting this gut-derived chemical modification plays a direct role in driving metabolic dysfunction and liver damage.
Detailed Summary
Metabolic diseases like obesity and fatty liver disease are increasingly linked to disturbances in the gut microbiome, but the precise molecular mechanisms connecting gut bacteria to organ dysfunction remain poorly understood. This study illuminates a striking new pathway through which gut bacteria directly alter liver cell biology at the molecular level.
Researchers identified a novel protein modification — lysine phenylacetylation (Kpaa) — produced when gut bacteria metabolize the amino acid phenylalanine into phenylacetic acid (PAA). This acid enters circulation and chemically tags liver proteins in a way not previously described. The finding adds phenylacetylation to the growing list of gut-derived post-translational modifications that shape host physiology.
In mice fed a high-fat diet, hepatic Kpaa levels were significantly elevated compared to lean controls. Proteome-wide analysis revealed that the proteins most affected by this modification are concentrated in mitochondria — the cell's energy-producing organelles. PAA treatment disrupted mitochondrial function and blunted insulin signaling, two hallmarks of metabolic disease. A key mechanistic finding was that PAA-induced Kpaa modification of HSP60 (a mitochondrial chaperone protein) at the K481 site triggered the mitochondrial unfolded protein response, a stress pathway linked to organelle damage.
Critically, the deacylase enzyme SIRT3 — a mitochondrial sirtuin — was shown to remove Kpaa modifications and reverse these harmful effects. In human samples from adults with obesity and metabolic dysfunction-associated steatohepatitis (MASH), SIRT3 levels were low while Kpaa levels were elevated, with the two inversely correlated.
This research is limited by reliance on the abstract only, and mechanistic validation in human tissue remains incomplete. Nonetheless, it identifies a compelling gut-liver axis mechanism and positions both PAA production by gut bacteria and SIRT3 activity as potential therapeutic targets in metabolic liver disease.
Key Findings
- Gut bacteria convert phenylalanine into phenylacetic acid, which creates a new protein modification (Kpaa) in liver cells.
- Kpaa modifications accumulate in the livers of obese mice and humans with fatty liver disease (MASH).
- PAA disrupts mitochondrial function and impairs insulin signaling, contributing to metabolic dysfunction.
- SIRT3 enzyme removes Kpaa modifications, reversing mitochondrial stress triggered by PAA-modified HSP60.
- Low SIRT3 and high Kpaa levels are inversely correlated in humans with obesity and liver disease.
Methodology
The study used high-fat-diet mouse models to assess hepatic Kpaa levels, combined with proteome-wide substrate mapping to identify mitochondrial targets. Human liver samples from adults with obesity and MASH were analyzed to correlate SIRT3 expression and Kpaa levels, and mechanistic experiments investigated PAA's effects on mitochondrial function and insulin signaling.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, so methodological details and data robustness cannot be fully evaluated. The mechanistic findings are primarily from animal models, and causal validation in human tissue is not confirmed from the available information. The clinical human data are correlational, limiting conclusions about causation in MASH patients.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: